139 related articles for article (PubMed ID: 28076841)
21. Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation.
Soerensen JF; Aggerholm A; Rosenberg CA; Bill M; Kerndrup GB; Ebbesen LH; Hansen MH; Roug AS; Ludvigsen M
Bone Marrow Transplant; 2022 Mar; 57(3):460-465. PubMed ID: 35027675
[TBL] [Abstract][Full Text] [Related]
22. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia.
Batzios C; Hayes LA; He SZ; Quach H; McQuilten ZK; Wall M; Campbell LJ
Am J Hematol; 2009 Nov; 84(11):715-9. PubMed ID: 19806661
[TBL] [Abstract][Full Text] [Related]
23. Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies.
Zhang X; Lv D; Zhang Y; Liu Q; Li Z
Oncotarget; 2016 Sep; 7(36):58586-58594. PubMed ID: 27474172
[TBL] [Abstract][Full Text] [Related]
24. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
[TBL] [Abstract][Full Text] [Related]
25. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
[TBL] [Abstract][Full Text] [Related]
26. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
[TBL] [Abstract][Full Text] [Related]
27. Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.
Langabeer SE; Haslam K; Kelly J; Quinn J; Morrell R; Conneally E
Clin Transl Oncol; 2018 Mar; 20(3):420-423. PubMed ID: 28762112
[TBL] [Abstract][Full Text] [Related]
28. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
Larson RA; Le Beau MM
Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
[TBL] [Abstract][Full Text] [Related]
29. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia.
Paguirigan AL; Smith J; Meshinchi S; Carroll M; Maley C; Radich JP
Sci Transl Med; 2015 Apr; 7(281):281re2. PubMed ID: 25834112
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Kandarpa M; Wu YM; Robinson D; Burke PW; Chinnaiyan AM; Talpaz M
Am J Hematol; 2017 Jun; 92(6):555-561. PubMed ID: 28335073
[TBL] [Abstract][Full Text] [Related]
31. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
Bullinger L; Döhner K; Döhner H
J Clin Oncol; 2017 Mar; 35(9):934-946. PubMed ID: 28297624
[TBL] [Abstract][Full Text] [Related]
32. Distinguishing clonal evolution from so-called secondary acute myelogenous leukemia: Adhering to unifying concepts of the genetic basis of leukemogenesis.
Lichtman MA
Blood Cells Mol Dis; 2015 Jun; 55(1):1-2. PubMed ID: 25976458
[No Abstract] [Full Text] [Related]
33. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
[TBL] [Abstract][Full Text] [Related]
34. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
35. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Goswami RS; Patel KP; Singh RR; Meric-Bernstam F; Kopetz ES; Subbiah V; Alvarez RH; Davies MA; Jabbar KJ; Roy-Chowdhuri S; Lazar AJ; Medeiros LJ; Broaddus RR; Luthra R; Routbort MJ
Clin Cancer Res; 2015 Jun; 21(11):2644-51. PubMed ID: 25695693
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.
Fianchi L; Pagano L; Piciocchi A; Candoni A; Gaidano G; Breccia M; Criscuolo M; Specchia G; Maria Pogliani E; Maurillo L; Aloe-Spiriti MA; Mecucci C; Niscola P; Rossetti E; Mansueto G; Rondoni M; Fozza C; Invernizzi R; Spadea A; Fenu S; Buda G; Gobbi M; Fabiani E; Sica S; Hohaus S; Leone G; Voso MT
Am J Hematol; 2015 May; 90(5):E80-5. PubMed ID: 25653205
[TBL] [Abstract][Full Text] [Related]
37. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
38. Morphological and cytogenetic changes in therapy-related leukemia developed in a t(8;21)-acute myeloid leukemia (M2) patient: sequential cytogenetic and molecular analyses.
Nawata R; Shinohara K; Yamada T; Takahashi T; Katsuki K; Takeda K; Kameda N; Ariyoshi K; Ota I; Muraki K
Int J Hematol; 2000 Jun; 71(4):353-8. PubMed ID: 10905055
[TBL] [Abstract][Full Text] [Related]
39. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
